Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B).

Details

Ressource 1Download: serval:BIB_CAF879C9E5D2.P001 (128.40 [Ko])
State: Public
Version: author
License: Not specified
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
Serval ID
serval:BIB_CAF879C9E5D2
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B).
Journal
Annals of Oncology
Author(s)
Ketterer N., Coiffier B., Thieblemont C., Fermé C., Brière J., Casasnovas O., Bologna S., Christian B., Connerotte T., Récher C., Bordessoule D., Fruchart C., Delarue R., Bonnet C., Morschhauser F., Anglaret B., Soussain C., Fabiani B., Tilly H., Haioun C.
ISSN
1569-8041 (Electronic)
ISSN-L
0923-7534
Publication state
Published
Issued date
2013
Volume
24
Number
4
Pages
1032-1037
Language
english
Notes
Publication types: Journal ArticlePublication Status: ppublish
Abstract
Background The superiority of a chemotherapy with doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone (ACVBP) in comparison with cyclophosphamide, doxorubicin, vincristin and prednisone plus radiotherapy for young patients with localized diffuse large B-cell lymphoma (DLBCL) was previously demonstrated. We report the results of a trial which evaluates the role of rituximab combined with ACVBP (R-ACVBP) in these patients. Patients and methods Untreated patients younger than 66 years with stage I or II DLBCL and no adverse prognostic factors of the age-adjusted International Prognostic Index were randomly assigned to receive three cycles of ACVBP plus sequential consolidation with or without the addition of four infusions of rituximab. Results A total of 223 patients were randomly allocated to the study, 110 in the R-ACVBP group and 113 in the ACVBP group. After a median follow-up of 43 months, our 3-year estimate of event-free survival was 93% in the R-ACVBP group and 82% in the ACVBP group (P = 0.0487). Three-year estimate of progression-free survival was increased in the R-ACVBP group (95% versus 83%, P = 0.0205). Overall survival did not differ between the two groups with a 3-year estimates of 98% and 97%, respectively (P = 0.686). Conclusion In young patients with low-risk localized DLBCL, rituximab combined with three cycles of ACVBP plus consolidation is significantly superior to ACVBP plus consolidation alone.
Pubmed
Web of science
Open Access
Yes
Create date
25/04/2013 17:00
Last modification date
25/09/2019 6:10
Usage data